Platelet Lysate
Identification
- Generic Name
- Platelet Lysate
- DrugBank Accession Number
- DB15869
- Background
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.1 It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- Platelet Lysate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Platelet lysate plays a role in regeneration through the growth factors it contains, resulting in an increase in cell proliferation and angiogenesis. Nebulized platelet lysate can be administered to the lungs and has applications in treatment of acute lung injuries, chronic obstructive pulmonary disease (COPD), and asthma. Because of the aforementioned diseases that the plasma lysate can treat and its ability to relegate severe inflammatory processes of the respiratory tract, it is currently also being investigated against COVID-19 infection-related acute respiratory syndrome (ARDS).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A2WX2UCW6F
- CAS number
- Not Available
References
- General References
- Jeyaraman M, Ranjan R, Kumar R, Arora A, Chaudhary D, Ajay SS, Jain R: Cellular Therapy: Shafts of Light Emerging for COVID-19. Stem Cell Investig. 2020 Jun 30;7:11. doi: 10.21037/sci-2020-022. eCollection 2020. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Knee Joint Osteoarthrosis 1 1, 2 Completed Treatment Acne Scarring 1 1, 2 Completed Treatment Critical Limb Ischemia (CLI) 1 1, 2 Completed Treatment Persistent Corneal Epithelial Defects 1 1, 2 Recruiting Treatment Diabetic Foot Ulcers (DFUs) 1 1, 2 Recruiting Treatment Peripheral Arterial Disease (PAD) 1 1, 2 Unknown Status Treatment Androgenetic Alopecia (AGA) 2 1, 2 Unknown Status Treatment Lateral Epicondylitis (Tennis Elbow) 1 Not Available Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 21, 2020 16:33 / Updated on September 22, 2020 13:00